NEW YORK (GenomeWeb) – The American Society of Clinical Oncology has updated its clinical practice guidelines, clarifying the role of immunotherapy in the treatment of patients with advanced non-small-cell lung cancer and providing new recommendations on the use of targeted therapies for patients with EGFR, ALK, and ROS1 alterations.